EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations

A. Nast; C. Smith; P. I. Spuls; G. Avila Valle; Z. Bata-Csörgö; H. Boonen; E. De Jong; I. Garcia-Doval; P. Gisondi; D. Kaur-Knudsen; S. Mahil; T. Mälkönen; J. T. Maul; S. Mburu; U. Mrowietz; K. Reich; E. Remenyik; K. M. Rønholt; P. G. Sator; M. Schmitt-Egenolf; M. Sikora; K. Strömer; O. Sundnes; D. Trigos; G. Van Der Kraaij; N. Yawalkar; C. Dressler

doi:10.1111/jdv.16915

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations

A. Nast^*, C. Smith, P. I. Spuls, G. Avila Valle, Z. Bata-Csörgö, H. Boonen, E. De Jong, I. Garcia-Doval, P. Gisondi, D. Kaur-Knudsen, S. Mahil, T. Mälkönen, J. T. Maul, S. Mburu, U. Mrowietz, K. Reich, E. Remenyik, K. M. Rønholt, P. G. Sator, M. Schmitt-EgenolfM. Sikora, K. Strömer, O. Sundnes, D. Trigos, G. Van Der Kraaij, N. Yawalkar, C. Dressler

^*Corresponding author af dette arbejde

Institut for Klinisk Medicin - Hjerte-, Lunge- og Karkirurgi

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

3 Citationer (Scopus)

67 Downloads (Pure)

Abstract

This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.

Originalsprog	Engelsk
Tidsskrift	Journal of the European Academy of Dermatology & Venereology
Vol/bind	34
Nummer	11
Sider (fra-til)	2461-2498
Antal sider	38
ISSN	0926-9959
DOI	https://doi.org/10.1111/jdv.16915
Status	Udgivet - nov. 2020

Adgang til dokumentet

10.1111/jdv.16915Licens: CC BY-NC

jdv.16915Forlagets udgivne version, 1,71 MBLicens: CC BY-NC

Andre filer og links

Link to publication in Scopus

Citationsformater

Nast, A., Smith, C., Spuls, P. I., Avila Valle, G., Bata-Csörgö, Z., Boonen, H., De Jong, E., Garcia-Doval, I., Gisondi, P., Kaur-Knudsen, D., Mahil, S., Mälkönen, T., Maul, J. T., Mburu, S., Mrowietz, U., Reich, K., Remenyik, E., Rønholt, K. M., Sator, P. G., ... Dressler, C. (2020). EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations. Journal of the European Academy of Dermatology & Venereology, 34(11), 2461-2498. https://doi.org/10.1111/jdv.16915

@article{bba0e56be2e7498bb171fb87eeb724e4,

title = "EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations",

abstract = "This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.",

author = "A. Nast and C. Smith and Spuls, {P. I.} and {Avila Valle}, G. and Z. Bata-Cs{\"o}rg{\"o} and H. Boonen and {De Jong}, E. and I. Garcia-Doval and P. Gisondi and D. Kaur-Knudsen and S. Mahil and T. M{\"a}lk{\"o}nen and Maul, {J. T.} and S. Mburu and U. Mrowietz and K. Reich and E. Remenyik and R{\o}nholt, {K. M.} and Sator, {P. G.} and M. Schmitt-Egenolf and M. Sikora and K. Str{\"o}mer and O. Sundnes and D. Trigos and {Van Der Kraaij}, G. and N. Yawalkar and C. Dressler",

note = "Publisher Copyright: {\textcopyright} 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2020",

month = nov,

doi = "10.1111/jdv.16915",

language = "English",

volume = "34",

pages = "2461--2498",

journal = "Journal of the European Academy of Dermatology & Venereology",

issn = "0926-9959",

publisher = "Elsevier",

number = "11",

}

Nast, A, Smith, C, Spuls, PI, Avila Valle, G, Bata-Csörgö, Z, Boonen, H, De Jong, E, Garcia-Doval, I, Gisondi, P, Kaur-Knudsen, D, Mahil, S, Mälkönen, T, Maul, JT, Mburu, S, Mrowietz, U, Reich, K, Remenyik, E, Rønholt, KM, Sator, PG, Schmitt-Egenolf, M, Sikora, M, Strömer, K, Sundnes, O, Trigos, D, Van Der Kraaij, G, Yawalkar, N & Dressler, C 2020, 'EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations', Journal of the European Academy of Dermatology & Venereology, bind 34, nr. 11, s. 2461-2498. https://doi.org/10.1111/jdv.16915

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations. / Nast, A.; Smith, C.; Spuls, P. I. et al.
I: Journal of the European Academy of Dermatology & Venereology, Bind 34, Nr. 11, 11.2020, s. 2461-2498.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

TY - JOUR

T1 - EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1

T2 - treatment and monitoring recommendations

AU - Nast, A.

AU - Smith, C.

AU - Spuls, P. I.

AU - Avila Valle, G.

AU - Bata-Csörgö, Z.

AU - Boonen, H.

AU - De Jong, E.

AU - Garcia-Doval, I.

AU - Gisondi, P.

AU - Kaur-Knudsen, D.

AU - Mahil, S.

AU - Mälkönen, T.

AU - Maul, J. T.

AU - Mburu, S.

AU - Mrowietz, U.

AU - Reich, K.

AU - Remenyik, E.

AU - Rønholt, K. M.

AU - Sator, P. G.

AU - Schmitt-Egenolf, M.

AU - Sikora, M.

AU - Strömer, K.

AU - Sundnes, O.

AU - Trigos, D.

AU - Van Der Kraaij, G.

AU - Yawalkar, N.

AU - Dressler, C.

N1 - Publisher Copyright: © 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2020/11

Y1 - 2020/11

N2 - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.

AB - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.

UR - http://www.scopus.com/inward/record.url?scp=85097922665&partnerID=8YFLogxK

U2 - 10.1111/jdv.16915

DO - 10.1111/jdv.16915

M3 - Journal article

C2 - 33349983

AN - SCOPUS:85097922665

SN - 0926-9959

VL - 34

SP - 2461

EP - 2498

JO - Journal of the European Academy of Dermatology & Venereology

JF - Journal of the European Academy of Dermatology & Venereology

IS - 11

ER -

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater